{"podcast":{"title":"The Evidence Based Rheumatology Podcast","slug":"the-evidence-based-rheumatology-podcast-1130175","podcast_index_feed_id":1130175,"rss_url":"https://feed.podbean.com/msputman/feed.xml","website_url":"https://msputman.podbean.com","image_url":"https://pbcdn1.podbean.com/imglogo/image-logo/2361093/Rheum_Logo-_canvas_size-2.jpg","author":"Michael Putman","episode_count":100,"summary":"A podcast for physicians about evidence based medicine in rheumatology. Each week we'll critique and apply a paper in the medical literature.","last_synced_at":"2026-07-25T20:19:21.829723+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175"},"episodes":[{"title":"E138: Dapirolizumab for SLE (PHOENYCS-GO)","slug":"e138-dapirolizumab-for-sle-phoenycs-go","published_at":"2026-07-24T20:33:26+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e138-dapirolizumab-for-sle-phoenycs-go","url":"https://msputman.podbean.com/e/e138-dapirolizumab-for-sle-phoenycs-go/","duration_seconds":1329,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e138-dapirolizumab-for-sle-phoenycs-go/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e138-dapirolizumab-for-sle-phoenycs-go.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E137: Obexelimab in IgG4-RD (INDIGO)","slug":"e137-obexelimab-in-igg4-rd-indigo","published_at":"2026-06-29T19:14:56+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e137-obexelimab-in-igg4-rd-indigo","url":"https://msputman.podbean.com/e/e137-obexelimab-in-igg4-rd-indigo/","duration_seconds":936,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e137-obexelimab-in-igg4-rd-indigo/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e137-obexelimab-in-igg4-rd-indigo.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E136: Secukinumab in PMR (REPLENISH)","slug":"e136-secukinumab-in-pmr-replenish","published_at":"2026-06-15T14:12:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e136-secukinumab-in-pmr-replenish","url":"https://msputman.podbean.com/e/e136-secukinumab-in-pmr-replenish/","duration_seconds":819,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e136-secukinumab-in-pmr-replenish/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e136-secukinumab-in-pmr-replenish.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E135: IL17 and a GLP1?","slug":"e135-il17-and-a-glp1","published_at":"2026-04-30T13:43:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e135-il17-and-a-glp1","url":"https://msputman.podbean.com/e/e135-il17-and-a-glp1/","duration_seconds":663,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e135-il17-and-a-glp1/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e135-il17-and-a-glp1.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E134: Brepocitinib in Dermatomyositis (VALOR)","slug":"e134-brepocitinib-in-dermatomyositis-valor","published_at":"2026-04-17T20:06:48+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e134-brepocitinib-in-dermatomyositis-valor","url":"https://msputman.podbean.com/e/e134-brepocitinib-in-dermatomyositis-valor/","duration_seconds":898,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e134-brepocitinib-in-dermatomyositis-valor/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e134-brepocitinib-in-dermatomyositis-valor.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E133: Obinutuzumab for SLE (ALLEGORY)","slug":"e133-obinutuzumab-for-sle-allegory","published_at":"2026-03-19T19:32:38+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e133-obinutuzumab-for-sle-allegory","url":"https://msputman.podbean.com/e/e133-obinutuzumab-for-sle-allegory/","duration_seconds":921,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e133-obinutuzumab-for-sle-allegory/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e133-obinutuzumab-for-sle-allegory.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)","slug":"e132-romosozumab-vs-teriparatide-for-osteoproosis-structure","published_at":"2026-03-05T15:54:58+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e132-romosozumab-vs-teriparatide-for-osteoproosis-structure","url":"https://msputman.podbean.com/e/e132-romosozumab-vs-teriparatide-for-osteoproosis-structure/","duration_seconds":834,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e132-romosozumab-vs-teriparatide-for-osteoproosis-structure/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e132-romosozumab-vs-teriparatide-for-osteoproosis-structure.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E131: A Sham-Controlled Sham of a Trial: RESET-RA","slug":"e131-a-sham-controlled-sham-of-a-trial-reset-ra","published_at":"2026-01-21T18:05:16+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e131-a-sham-controlled-sham-of-a-trial-reset-ra","url":"https://msputman.podbean.com/e/e131-a-sham-controlled-sham-of-a-trial-reset-ra/","duration_seconds":888,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e131-a-sham-controlled-sham-of-a-trial-reset-ra/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e131-a-sham-controlled-sham-of-a-trial-reset-ra.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E130: Telitacicept for SLE","slug":"e130-telitacicept-for-sle","published_at":"2025-12-22T23:07:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e130-telitacicept-for-sle","url":"https://msputman.podbean.com/e/e130-telitacicept-for-sle/","duration_seconds":786,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e130-telitacicept-for-sle/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e130-telitacicept-for-sle.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E129: Long Term Routine Laboratory Monitoring in RA","slug":"e129-long-term-routine-laboratory-monitoring-in-ra","published_at":"2025-12-04T13:02:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e129-long-term-routine-laboratory-monitoring-in-ra","url":"https://msputman.podbean.com/e/e129-long-term-routine-laboratory-monitoring-in-ra/","duration_seconds":917,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e129-long-term-routine-laboratory-monitoring-in-ra/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e129-long-term-routine-laboratory-monitoring-in-ra.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E128: Nerandomilast for Autoimmune ILD (FIBRONEER-ILD)","slug":"e128-nerandomilast-for-autoimmune-ild-fibroneer-ild","published_at":"2025-11-12T18:07:48+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild","url":"https://msputman.podbean.com/e/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild/","duration_seconds":1143,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e128-nerandomilast-for-autoimmune-ild-fibroneer-ild.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E127: TNFs and All That CHF","slug":"e127-tnfs-and-all-that-chf","published_at":"2025-09-22T18:22:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e127-tnfs-and-all-that-chf","url":"https://msputman.podbean.com/e/e127-tnfs-and-all-that-chf/","duration_seconds":1306,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e127-tnfs-and-all-that-chf/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e127-tnfs-and-all-that-chf.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E126: Risk Signals, JAKs, and SELECTIVE-ity","slug":"e126-risk-signals-jaks-and-selective-ity","published_at":"2025-09-08T17:45:15+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e126-risk-signals-jaks-and-selective-ity","url":"https://msputman.podbean.com/e/e126-risk-signals-jaks-and-selective-ity/","duration_seconds":874,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e126-risk-signals-jaks-and-selective-ity/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e126-risk-signals-jaks-and-selective-ity.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E125: Adrenal Insufficiency after Stopping Prednisone","slug":"e125-adrenal-insufficiency-after-stopping-prednisone","published_at":"2025-06-29T20:52:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e125-adrenal-insufficiency-after-stopping-prednisone","url":"https://msputman.podbean.com/e/e125-adrenal-insufficiency-after-stopping-prednisone/","duration_seconds":1072,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e125-adrenal-insufficiency-after-stopping-prednisone/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e125-adrenal-insufficiency-after-stopping-prednisone.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"e124: MTX vs Pred for Pulmonary Sarcoidosis: PREDMETH Study","slug":"e124-mtx-vs-pred-for-pulmonary-sarcoidosis-predmeth-study","published_at":"2025-06-12T16:27:43+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e124-mtx-vs-pred-for-pulmonary-sarcoidosis-predmeth-study","url":"https://msputman.podbean.com/e/e124-mtx-vs-pred-for-pulmonary-sarcoidosis-predmeth-study/","duration_seconds":858,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e124-mtx-vs-pred-for-pulmonary-sarcoidosis-predmeth-study/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e124-mtx-vs-pred-for-pulmonary-sarcoidosis-predmeth-study.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E123: Upadacitinib for Giant Cell Arteritis: SELECT-GCA","slug":"e123-upadacitinib-for-giant-cell-arteritis-select-gca","published_at":"2025-04-30T15:33:13+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e123-upadacitinib-for-giant-cell-arteritis-select-gca","url":"https://msputman.podbean.com/e/e123-upadacitinib-for-giant-cell-arteritis-select-gca/","duration_seconds":1093,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e123-upadacitinib-for-giant-cell-arteritis-select-gca/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e123-upadacitinib-for-giant-cell-arteritis-select-gca.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E122: Guidelines for Maybe Diagnosing HLH","slug":"e122-guidelines-for-maybe-diagnosing-hlh","published_at":"2025-04-17T17:26:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e122-guidelines-for-maybe-diagnosing-hlh","url":"https://msputman.podbean.com/e/e122-guidelines-for-maybe-diagnosing-hlh/","duration_seconds":678,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e122-guidelines-for-maybe-diagnosing-hlh/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e122-guidelines-for-maybe-diagnosing-hlh.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E121: Obinutuzumab in SLE-LN","slug":"e121-obinutuzumab-in-sle-ln","published_at":"2025-04-02T17:07:44+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e121-obinutuzumab-in-sle-ln","url":"https://msputman.podbean.com/e/e121-obinutuzumab-in-sle-ln/","duration_seconds":1094,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e121-obinutuzumab-in-sle-ln/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e121-obinutuzumab-in-sle-ln.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E120: Real Life Use of PEXIVAS-Low","slug":"e120-real-life-use-of-pexivas-low","published_at":"2025-03-06T17:00:14+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e120-real-life-use-of-pexivas-low","url":"https://msputman.podbean.com/e/e120-real-life-use-of-pexivas-low/","duration_seconds":1473,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e120-real-life-use-of-pexivas-low/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e120-real-life-use-of-pexivas-low.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E119: Teclistamab for Rheumatology Writ Large","slug":"e119-teclistamab-for-rheumatology-writ-large","published_at":"2025-02-10T16:55:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e119-teclistamab-for-rheumatology-writ-large","url":"https://msputman.podbean.com/e/e119-teclistamab-for-rheumatology-writ-large/","duration_seconds":652,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e119-teclistamab-for-rheumatology-writ-large/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e119-teclistamab-for-rheumatology-writ-large.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E118: The emerging risk of overdiagnosis in RA and PMR","slug":"e118-the-emerging-risk-of-overdiagnosis-in-ra-and-pmr","published_at":"2025-01-31T15:42:47+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e118-the-emerging-risk-of-overdiagnosis-in-ra-and-pmr","url":"https://msputman.podbean.com/e/e118-the-emerging-risk-of-overdiagnosis-in-ra-and-pmr/","duration_seconds":962,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e118-the-emerging-risk-of-overdiagnosis-in-ra-and-pmr/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e118-the-emerging-risk-of-overdiagnosis-in-ra-and-pmr.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E117: Inebilizumab for IgG4-RD (MITIGATE)","slug":"e117-inebilizumab-for-igg4-rd-mitigate","published_at":"2024-12-03T16:55:35+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e117-inebilizumab-for-igg4-rd-mitigate","url":"https://msputman.podbean.com/e/e117-inebilizumab-for-igg4-rd-mitigate/","duration_seconds":775,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e117-inebilizumab-for-igg4-rd-mitigate/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e117-inebilizumab-for-igg4-rd-mitigate.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E116: A New Paradigm for PMR","slug":"e116-a-new-paradigm-for-pmr","published_at":"2024-11-11T19:32:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e116-a-new-paradigm-for-pmr","url":"https://msputman.podbean.com/e/e116-a-new-paradigm-for-pmr/","duration_seconds":569,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e116-a-new-paradigm-for-pmr/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e116-a-new-paradigm-for-pmr.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E115: Benralizumab for EGPA - the MANDARA Study","slug":"e115-benralizumab-for-egpa-the-mandara-study","published_at":"2024-10-28T18:31:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e115-benralizumab-for-egpa-the-mandara-study","url":"https://msputman.podbean.com/e/e115-benralizumab-for-egpa-the-mandara-study/","duration_seconds":592,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e115-benralizumab-for-egpa-the-mandara-study/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e115-benralizumab-for-egpa-the-mandara-study.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"E114: Target Trials and STAR-RA with Rishi Desai","slug":"e114-target-trials-and-star-ra-with-rishi-desai","published_at":"2024-10-14T18:26:00+00:00","page_url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e114-target-trials-and-star-ra-with-rishi-desai","url":"https://msputman.podbean.com/e/e114-target-trials-and-star-ra-with-rishi-desai/","duration_seconds":1875,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-evidence-based-rheumatology-podcast-1130175/episodes/e114-target-trials-and-star-ra-with-rishi-desai/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-evidence-based-rheumatology-podcast-1130175/e114-target-trials-and-star-ra-with-rishi-desai.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}]}